These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 24198624)

  • 21. Poly[allylamine hydrochloride] (RenaGel): a noncalcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure.
    Chertow GM; Burke SK; Lazarus JM; Stenzel KH; Wombolt D; Goldberg D; Bonventre JV; Slatopolsky E
    Am J Kidney Dis; 1997 Jan; 29(1):66-71. PubMed ID: 9002531
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A comparative study of phosphate binders in patients with end stage kidney disease undergoing hemodialysis.
    Prajapati VA; Galani VJ; Shah PR
    Saudi J Kidney Dis Transpl; 2014 May; 25(3):530-8. PubMed ID: 24821148
    [TBL] [Abstract][Full Text] [Related]  

  • 23. RenaGel, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone. The RenaGel Study Group.
    Slatopolsky EA; Burke SK; Dillon MA
    Kidney Int; 1999 Jan; 55(1):299-307. PubMed ID: 9893140
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A comparative review of the efficacy and safety of established phosphate binders: calcium, sevelamer, and lanthanum carbonate.
    Sprague SM
    Curr Med Res Opin; 2007 Dec; 23(12):3167-75. PubMed ID: 17991307
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effectiveness and cost-efficacy of phosphate binders in hemodialysis.
    Brunner-Ziegler S; Fröschl B; Hiebinger C; Zsifkovits J
    Ann Nutr Metab; 2011 Oct; 58(4):315-9. PubMed ID: 21986491
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term comparison of a calcium-free phosphate binder and calcium carbonate--phosphorus metabolism and cardiovascular calcification.
    Braun J; Asmus HG; Holzer H; Brunkhorst R; Krause R; Schulz W; Neumayer HH; Raggi P; Bommer J
    Clin Nephrol; 2004 Aug; 62(2):104-15. PubMed ID: 15356967
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sevelamer revisited: pleiotropic effects on endothelial and cardiovascular risk factors in chronic kidney disease and end-stage renal disease.
    Rastogi A
    Ther Adv Cardiovasc Dis; 2013 Dec; 7(6):322-42. PubMed ID: 24327730
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effectiveness and cost-efficiency of phosphate binders in hemodialysis.
    Fröschl B; Brunner-Ziegler S; Hiebinger C; Wimmer A; Zsifkovits J
    GMS Health Technol Assess; 2009 Jun; 5():Doc08. PubMed ID: 21289895
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sevelamer carbonate in the treatment of hyperphosphatemia in patients with chronic kidney disease on hemodialysis.
    Savica V; Santoro D; Monardo P; Mallamace A; Bellinghieri G
    Ther Clin Risk Manag; 2008 Aug; 4(4):821-6. PubMed ID: 19209264
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intensive Hemodialysis, Mineral and Bone Disorder, and Phosphate Binder Use.
    Copland M; Komenda P; Weinhandl ED; McCullough PA; Morfin JA
    Am J Kidney Dis; 2016 Nov; 68(5S1):S24-S32. PubMed ID: 27772640
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis.
    Block GA; Spiegel DM; Ehrlich J; Mehta R; Lindbergh J; Dreisbach A; Raggi P
    Kidney Int; 2005 Oct; 68(4):1815-24. PubMed ID: 16164659
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sevelamer hydrochloride in peritoneal dialysis patients: results of a multicenter cross-sectional study.
    Ramos R; Moreso F; Borras M; Ponz E; Buades JM; Teixidó J; Morey A; Garcia C; Vera M; Doñate MT; de Arellano MR; Barbosa F; González MT
    Perit Dial Int; 2007; 27(6):697-701. PubMed ID: 17984434
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Management of hyperphosphataemia in dialysis patients: role of phosphate binders in the elderly.
    Lorenzo Sellares V; Torres Ramírez A
    Drugs Aging; 2004; 21(3):153-65. PubMed ID: 14979734
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phosphate-Binder Use in US Dialysis Patients: Prevalence, Costs, Evidence, and Policies.
    St Peter WL; Wazny LD; Weinhandl ED
    Am J Kidney Dis; 2018 Feb; 71(2):246-253. PubMed ID: 29195858
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phosphate-Binding Agents in Adults With CKD: A Network Meta-analysis of Randomized Trials.
    Palmer SC; Gardner S; Tonelli M; Mavridis D; Johnson DW; Craig JC; French R; Ruospo M; Strippoli GF
    Am J Kidney Dis; 2016 Nov; 68(5):691-702. PubMed ID: 27461851
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical and economic aspects of sevelamer therapy in end-stage renal disease patients.
    Ossareh S
    Int J Nephrol Renovasc Dis; 2014; 7():161-8. PubMed ID: 24855385
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The role of sevelamer in achieving the kidney disease outcomes quality initiative (K/DOQI) guidelines for hyperphosphatemia.
    Pai AB; Smeeding JE; Brook RA
    Curr Med Res Opin; 2004 Jul; 20(7):991-9. PubMed ID: 15265243
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effects of sevelamer hydrochloride and calcium carbonate on kidney calcification in uremic rats.
    Cozzolino M; Dusso AS; Liapis H; Finch J; Lu Y; Burke SK; Slatopolsky E
    J Am Soc Nephrol; 2002 Sep; 13(9):2299-308. PubMed ID: 12191974
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Health and economic consequences of sevelamer use for hyperphosphatemia in patients on hemodialysis.
    Huybrechts KF; Caro JJ; Wilson DA; O'Brien JA
    Value Health; 2005; 8(5):549-61. PubMed ID: 16176493
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hyperphosphataemia: treatment options.
    Malberti F
    Drugs; 2013 May; 73(7):673-88. PubMed ID: 23625273
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.